Document Detail


Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.
MedLine Citation:
PMID:  23358426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We present a patient with metastatic BRAF-mutated melanoma who achieved long-term stabilization of leptomeningeal disease (LMD) with sequential whole-brain radiation therapy and vemurafenib. A 53-year-old woman with melanoma that harbored the BRAF V600E mutation and had that metastasized to multiple lymph nodes, lungs, breast, and subcutaneous tissue had developed symptomatic LMD 16 months after starting vemurafenib treatment despite achieving a substantial response at the existing metastatic sites. Vemurafenib was discontinued for 7 days, she received whole-brain radiation therapy (30 Gy in 10 fractions), and 7 days after completing the radiation therapy, she resumed vemurafenib therapy. The neurologic symptoms improved significantly, and a cerebrospinal fluid examination revealed disappearance of melanoma cells. She remained alive with radiologically stable LMD for at least 18 months after the whole-brain radiation therapy.
Authors:
Jee Min Lee; Urvi N Mehta; Ly H Dsouza; Beverly Ashleigh Guadagnolo; Deborah L Sanders; Kevin B Kim
Related Documents :
24409356 - Pretreatment platelet-to-lymphocyte ratio (plr) as a predictor of response to first-lin...
25051406 - Tumour cell proliferation (ki-67) in non-small cell lung cancer: a critical reappraisal...
9135526 - Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study.
7637046 - Laser treatment of localized squamous cell carcinoma of the penis.
1293006 - Neck metastasis from an occult primary--the kidwai experience.
19344426 - Prognostic factor analysis of the survival of elderly patients with aml in the mrc aml1...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Melanoma research     Volume:  23     ISSN:  1473-5636     ISO Abbreviation:  Melanoma Res.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-02-28     Completed Date:  2014-01-22     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-8     Citation Subset:  IM    
Copyright Information:
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brain Neoplasms / radiotherapy*,  secondary
Female
Humans
Indoles / therapeutic use*
Melanoma / drug therapy*,  pathology,  radiotherapy*
Meningeal Neoplasms / radiotherapy*,  secondary
Middle Aged
Skin Neoplasms / drug therapy*,  pathology,  radiotherapy*
Sulfonamides / therapeutic use*
Grant Support
ID/Acronym/Agency:
CA16672/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Indoles; 0/PLX4032; 0/Sulfonamides
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Can noninvasive imaging tools potentially predict the risk of ulceration in invasive melanomas showi...
Next Document:  What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the developme...